Takeuchi Y, Chang M R, Hashigaki K, Yamato M
Faculty of Pharmaceutical Sciences, Okayama University, Japan.
Chem Pharm Bull (Tokyo). 1991 Jun;39(6):1629-31. doi: 10.1248/cpb.39.1629.
Novel indolo[3,2-b]quinolines (1d-g), introduced at the 7-position with an N-glycosylamino group, were prepared and their antitumor activities against leukemia P388 in mice were examined. The N-Galactopyranosylamino derivative (1e) was a much more potent anti-leukemia compound (optimal dose = 25 mg/kg, T/C greater than 333%, cure 5/6) than lead compound 1a.
制备了在7位引入N-糖基氨基的新型吲哚并[3,2-b]喹啉（1d-g），并检测了它们对小鼠白血病P388的抗肿瘤活性。N-吡喃半乳糖基氨基衍生物（1e）是一种比先导化合物1a更有效的抗白血病化合物（最佳剂量=25mg/kg，T/C大于333%，治愈5/6）。
